Today, we have announced that the first patient has been dosed in our Phase 1 ONKORAS-101 trial for the study of BBO-8520 for those with non-small cell #lungcancer. Read more: https://lnkd.in/d52iWgMU
About us
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company advancing a next generation pipeline of novel small molecule therapeutics targeting RAS and PI3K malignancies. Initially formed as a subsidiary of BridgeBio, BridgeBio Oncology Therapeutics completed a $200M private financing with external investors in 2024 with the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors.
- Website
-
www.bridgebiooncology.com
External link for BridgeBio Oncology Therapeutics
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Type
- Privately Held
Employees at BridgeBio Oncology Therapeutics
Updates
-
We're thrilled to introduce BridgeBio Oncology Therapeutics (BBOT)! We’re on a mission to advance a next generation pipeline of novel #smallmolecule therapeutics targeting RAS and PI3K malignancies. Led by Eli Wallace, Ph.D., as chief executive officer and Pedro J. Beltran, Ph.D., as chief scientific officer, we're looking forward to advancing three initial programs with the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. Read today's full announcement below.